New Weight Loss Shots by Eli Lilly

Weight Loss Drug Demand Drives Eli Lilly Sales

Hosted on MSN · 1d

Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Business Insider · 1d

Eli Lilly (NYSE:LLY) Speeds Up Weight Loss Drug Data Release

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s leader can become

Yahoo · 1d

Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss

Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.

12d

Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

NBC New York25d

Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly and Novo Nordisk, which dominate the market with their obesity injections Zepbound and Wegovy, respectively, are both looking to develop next-generation versions. A weight loss ...

Nature2d

The weight-loss drugs being tested in 2025: will they beat Ozempic?

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Weight Loss Drug Demand Drives Eli Lilly Sales

Trending now